Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
Recruiting · NCT07226219 · Registry updated 2026-09-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease | Cognition Disorders, Cognitive Dysfunction, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, attention deficit hyperactivity disorder, inattentive type, cognitive disorder, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, neurodevelopmental disorder, oppositional defiant disorder, psychiatric disorder, sickle cell disease | Recruiting | Phase 1 | 2026-09-09 | NCT07226219 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| St. Jude Children's Research Hospital | 169 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| St. Jude Children's Research Hospital | Memphis | United States | 194 |